June 2020: Boston Scientific Corporation introduced DIRECTSENSE Technology, a device for tracking how radiofrequency (RF) energy is delivered during cardiac ablation procedures. Furthermore, the DIRECTSENSE Technology offers information on the impedance around the catheter tip to gauge the tissue's responsiveness to RF radiation.
August 2022: Medtronic plc acquired Affera, Inc. to extend the first-ever cardiac mapping and navigation platform, which includes radiofrequency ablation solution, to the company's cardiac ablation product line. Further, this acquisition gives the company access to the Affera Prism-1 cardiac mapping and navigation platform, which is compatible with both Medtronic therapeutic catheters and a variety of competing technologies.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4032
Published Date: Sep 26, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Growing preference for minimally invasive procedures and the growing prevalence of gastrointestinal diseases are the major factors driving the market growth.
The market size of gastrointestinal radiofrequency ablation systems is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are ATRICURE, INC, Royal Philips, Boston Scientific Corporation, Medtronic plc, Johnson & Johnson, Japan Lifeline Co. Ltd, Medtronic Japan Co. Ltd, Olympus Corporation, Astellas Pharma Inc. and others
The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.